Join Growin Stock Community!

Eli lilly and companyLLY.US Overview

US StockHealthcare
(No presentation for LLY)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LLY AI Insights

LLY Overall Performance

LLY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LLY Recent Performance

-1.64%

Eli lilly and company

0.05%

Avg of Sector

-0.31%

S&P500

LLY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LLY Key Information

LLY Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LLY Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Price of LLY

LLY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LLY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
21.88
PE Ratio (TTM)
45.88
Forward PE
34.93
PS Ratio (TTM)
15.23
PB Ratio
36.33
Price-to-FCF
107.03
METRIC
VALUE
vs. INDUSTRY
Gross Margin
83.04%
Net Margin
31.67%
Revenue Growth (YoY)
44.70%
Profit Growth (YoY)
47.79%
3-Year Revenue Growth
38.24%
3-Year Profit Growth
40.39%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
21.88
PE Ratio (TTM)
45.88
Forward PE
34.93
PS Ratio (TTM)
15.23
PB Ratio
36.33
Price-to-FCF
107.03
Gross Margin
83.04%
Net Margin
31.67%
Revenue Growth (YoY)
44.70%
Profit Growth (YoY)
47.79%
3-Year Revenue Growth
38.24%
3-Year Profit Growth
40.39%

  • When is LLY's latest earnings report released?

    The most recent financial report for Eli lilly and company (LLY) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LLY's short-term business performance and financial health. For the latest updates on LLY's earnings releases, visit this page regularly.

  • Where does LLY fall in the P/E River chart?

    According to historical valuation range analysis, Eli lilly and company (LLY)'s current price-to-earnings (P/E) ratio is 47.45, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of LLY?

    According to the latest financial report, Eli lilly and company (LLY) reported an Operating Profit of 8.84B with an Operating Margin of 45.81% this period, representing a growth of 75.39% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LLY's revenue growth?

    In the latest financial report, Eli lilly and company (LLY) announced revenue of 19.29B, with a Year-Over-Year growth rate of 42.56%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LLY have?

    As of the end of the reporting period, Eli lilly and company (LLY) had total debt of 42.5B, with a debt ratio of 0.38. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LLY have?

    At the end of the period, Eli lilly and company (LLY) held Total Cash and Cash Equivalents of 7.27B, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LLY go with three margins increasing?

    In the latest report, Eli lilly and company (LLY) achieved the “three margins increasing” benchmark, with a gross margin of 82.5%%, operating margin of 45.81%%, and net margin of 34.4%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LLY's profit trajectory and future growth potential.

  • Is LLY's EPS continuing to grow?

    According to the past four quarterly reports, Eli lilly and company (LLY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 7.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LLY?

    Eli lilly and company (LLY)'s Free Cash Flow (FCF) for the period is 677.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 30.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LLY?

    The latest valuation data shows Eli lilly and company (LLY) has a Price-To-Earnings (PE) ratio of 47.45 and a Price/Earnings-To-Growth (PEG) ratio of 1.9. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.